Neurocrine Biosciences (MEX:NBIX) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:NBIX Neurocrine Biosciences Inc MEX:NBIX
74 GF Score
Price MXN2,970.19
GF Value MXN3,308.85
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Neurocrine Biosciences FFO?

FFO (Funds from operations) only applies to REITs.

MEX:NBIX
74GF Score
Neurocrine Biosciences Inc MEX:NBIX
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Neurocrine Biosciences (MEX:NBIX) Overvalued in 2026?

Based on GuruFocus' analysis, Neurocrine Biosciences stock appears to be undervalued. The current stock price of MXN2,970.19 is trading 10.2% below its estimated GF Value™ of MXN3,308.85. GuruFocus considers Neurocrine Biosciences to be Modestly Undervalued.

Key valuation signals for MEX:NBIX:

  • FFO:
  • GF Value™: MXN3,308.85 vs. price of MXN2,970.19 (10.2% below fair value)
  • GF Score™: 74/100 with 6 warning signs

No single metric tells the full story. See the MEX:NBIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Neurocrine Biosciences Business Description

Address 6027 Edgewood Bend Court, San Diego, CA, USA, 92130
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
74GF Score

Get the complete analysis for MEX:NBIX

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN2,970.19
Price
MXN3,308.85
GF Value